Market Exclusive

Aclaris Therapeutics Inc (NASDAQ:ACRS) had its Buy rating reiterated by Cantor Fitzgerald with a $50.00 price target

Analyst Ratings For Aclaris Therapeutics Inc (NASDAQ:ACRS)

Today, Cantor Fitzgerald reiterated its Buy rating on Aclaris Therapeutics Inc (NASDAQ:ACRS) with a price target of $50.00.

There are 3 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Aclaris Therapeutics Inc (NASDAQ:ACRS) is Buy with a consensus target price of $45.3333 per share, a potential 623.02% upside.

Some recent analyst ratings include

Recent Trading Activity for Aclaris Therapeutics Inc (NASDAQ:ACRS)
Shares of Aclaris Therapeutics Inc closed the previous trading session at 6,27 −0,16 2,49 % with 6.52 shares trading hands.

Exit mobile version